Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.

Depressed T-lymphocyte function as assessed by delayed-type hypersensitivity reactions and in vitro proliferative response to mitogens is a characteristic finding in many types of solid tumors, including bladder carcinoma. Peripheral blood leukocytes from 16 patients with transitional cell carcinoma of the bladder were compared with age-matched, control subjects. Both the unfractionated leukocytes containing 10 to 30% monocytes and the lymphocyte-enriched preparations, obtained by monocyte depletion with iron filing ingestion, were analyzed. Mixed leukocyte culture-induced cytotoxicity was depressed in the patient group; the amount of depression was directly correlated to the extent of the disease. In patients who underwent surgical removal of tumor, the mixed leukocyte culture-induced cytotoxicity appeared normal. This mixed leukocyte culture-generated cytotoxic response was a more sensitive indicator of tumor effect than was the induced proliferative response. Removal of phagocytic or adherent monocytes from the responding cell population caused a significant increase in the generated cytotoxicity, especially in those patients with invasive disease. These suppressive effects could be partially reconstituted by quantitative addition of the separated monocytes back to the responding lymphocyte culture. The depressed lymphocyte-mediated cytotoxicity present in these bladder cancer patients was due, in a major part, to a circulating macrophage-like cell with active suppressor function.

Repair of abdominal aortic aneurysm by transfemoral endovascular graft placement.

PURPOSE: The authors describe the initial clinical experience with a new device, approved by the FDA for investigation, for repair of abdominal aortic aneurysm by transfemoral endovascular insertion of an aortic graft. METHODS: Sixty-nine patients with abdominal aortic aneurysms were screened, and ten were found to be suitable for endovascular grafting. Repair was done in the operating room using general anesthesia. One femoral artery was surgically exposed, and the device, containing a premeasured graft with proximal and distal self-expanding fixation devices, was inserted with fluoroscopic control through an open arteriotomy. FINDINGS: Eight of ten patients underwent successful graft placement, and two patients required conversion to an open repair. On follow-up, six of eight patients who underwent graft placement functioned normally, with documented aneurysm thrombosis. Two patients who underwent graft placement functioned normally, with contrast computed tomography evidence of incomplete aneurysm thrombosis, but without further expansion. CONCLUSION: Transfemoral repair is safe and appears to be effective. Phase II study currently is appropriate, with need for long-term follow-up.

Abdominal aortic aneurysm: a 6-year comparison of endovascular versus transabdominal repair.

OBJECTIVE: To test the hypothesis that endovascular repair of abdominal aortic aneurysm (AAA) will result in a significant reduction in mortality and morbidity rates and cost when compared with open transabdominal repair. SUMMARY BACKGROUND DATA: Since the introduction of endovascular repair of AAA this decade, multiple groups have evaluated different endovascular grafts. Despite the excellent results reported initially, there has been a paucity of well-controlled, comparative studies looking at long-term outcome. METHODS: From 1992 to 1998, the first 100 consecutive patients undergoing endovascular AAA repair (mean age 74.7, AAA size 5.6 cm) were compared to 100 patients undergoing transabdominal repair (mean age 72.9, AAA size 5.9 cm). All patients undergoing endovascular repair received a device manufactured by Endovascular Technologies, Inc. (Menlo Park, CA) and were prospectively followed with periodic examination, contrast-enhanced computed tomography, and duplex scanning. Of the 200 patients, 198 have been available for long-term follow-up. RESULTS: The two groups had similar preoperative risk factors. Surgical time (211 vs. 256 minutes, p < 0.005), blood loss (326 vs. 1010 ml, p < 0.005), and blood replacement (0.4 vs. 1.6 units, p < 0.005) were all decreased in the endovascular group. Median intensive care unit stay (0 vs. 2 days) and hospital stay (2 vs. 7 days) were significantly reduced in the endovascular group. Insignificant trends in lower morbidity rates (myocardial infarction 1 % vs. 5%, respiratory failure 1 % vs. 5%, colon ischemia 0% vs. 2%) were present in patients undergoing endovascular repair. This led to decreased hospital cost and increased hospital profit. The surgical mortality rate (2% vs. 3%) and 5-year survival rate (65% vs. 72%) have been equivalent between the two groups. CONCLUSIONS: The surgical mortality rate is low for both groups and not statistically different. Endovascular repair significantly reduces resource utilization (surgical time, blood replacement, intensive care unit and hospital stay) and cost when compared to transabdominal aneurysm repair. Long-term survival is equivalent in patients undergoing AAA repair regardless of technique. Although endovascular repair appears durable for up to 6 years, longer follow-up studies are warranted.

Repair of type IV thoracoabdominal aneurysm with a combined endovascular and surgical approach.

We report an unusual case of type IV Thoracoabdominal Aneurysm (TAA) with Superior Mesenteric Artery (SMA), celiac artery, and bilateral renal artery aneurysms in a patient who underwent an earlier repair of two infrarenal Abdominal Aortic Aneurysm (AAA) ruptures. Because of the presence of the visceral artery aneurysms and the earlier operation through the retroperitoneum, standard surgical treatment via a retroperitoneal approach with an inclusion grafting technique was considered difficult. A combined surgical approach achieving retrograde perfusion of all four visceral vessels and endovascular grafting allowing exclusion of the TAA was accomplished. Complete exclusion of the aneurysm and normal perfusion of the patient's viscera was documented by means of follow-up examinations at 3 and 6 months. The repair of a type IV TAA with a Combined Endovascular and Surgical Approach (CESA) allowed us to manage both the aortic and visceral aneurysms without thoracotomy or re-do retroperitoneal exposure and minimized visceral ischemia time. If the durability of this approach is confirmed, it may represent an attractive alternative in patients with aneurysmal involvement of the visceral segment of the aorta.

Selection process for surgeons in the Asymptomatic Carotid Atherosclerosis Study.

BACKGROUND AND PURPOSE: The Asymptomatic Carotid Atherosclerosis Study is a prospective, multicenter, randomized clinical trial of carotid endarterectomy for the treatment of asymptomatic hemodynamically significant stenosis. This report describes the selection process for participating surgeons in the trial. METHODS: The Surgical Management Committee established guidelines for minimal annual experience and maximum neurological morbidity and mortality for surgeons to qualify to participate in the study. For approval, a surgeon must perform at least 12 carotid endarterectomies per year. Based on a review of the surgeon's last 50 consecutive endarterectomies, the combined neurological morbidity and mortality rate must be no greater than 5% for all indications and no greater than 3% for endarterectomies performed on asymptomatic patients. RESULTS: One hundred sixty-four surgeons from 48 centers applied for approval: 117 were approved, 17 were rejected, and 30 were not reviewed. The 117 approved surgeons submitted a total of 5,641 endarterectomies with a combined mortality and neurological morbidity rate of 2.3% for the variety of indications for operation. CONCLUSIONS: This overall experience with carotid endarterectomy is one of the largest series reported to date. The data from approved surgeons are well within the range of acceptable neurological morbidity and mortality rates recommended by the Stroke Council of the American Heart Association, which attests to the overall quality of the surgeons participating in the study.

Benefit of carotid endarterectomy after prior stroke.

PURPOSE: The benefit of carotid endarterectomy (CEA) in preventing recurrent stroke in patients who have sustained a previous stroke remains controversial. The purpose of this study was to evaluate the immediate results and long-term benefit of CEA after recovery from a prior ipsilateral stroke. METHODS: Between 1980 and 1990, 85 patients underwent CEA for prior stroke with an average follow up of 54 months (range 0.3 to 130). The interval from prior stroke to CEA averaged 19.8 months (range 0.1 to 158.3). Vascular risk factors included hypertension in 70.6%, diabetes in 20.0%, history of smoking in 80.0%, and associated coronary artery disease in 51.8% of the patients. RESULTS: There were no perioperative deaths. Four patients (4.7%) had an ipsilateral stroke within 30 days of operation. During the follow up 31 patients (36.5%) died. The leading cause of death was cardiac (54.8%) followed by cancer (16.1%). By life-table methods, the cumulative incidence of recurrent stroke at 9 years was 14% for strokes in the ipsilateral distribution, for an annual stroke risk of 1.6% per year. The cumulative incidence of stroke in other distributions was 5%, for an annual stroke risk of 2.1% per year for all strokes. When interval to operation, preoperative stroke severity, vascular risk factors, and neurologic symptoms were evaluated, no independent indicator of increased risk of recurrent postoperative stroke could be identified. CONCLUSION: These results demonstrate a marked improvement over the natural history and best medical therapy for these lesions as reoperated in the literature. We conclude that CEA is beneficial in preventing recurrent stroke in this group of patients and should be considered the appropriate management in this setting.

Failure of PTFE infrainguinal revascularization: patterns, management alternatives, and outcome.

This review identifies the causes of PTFE infrainguinal bypass graft failure and compares the results of management alternatives. In 322 infrainguinal reconstructions 111 failures occurred over a ten year interval (1978-1988). Sixty-four percent of all failures occurred within the first year, most within the first six months due to severity or progression of distal disease (56%), which suggests that patient selection is an important factor. Only 8% of cases had intimal hyperplasia as a cause of failure without evidence of distal disease progression, and all occurred within the first twelve months. Progression of inflow disease occurred in 25% of instances and was most commonly seen as progression of iliac disease in patients operated upon to relieve claudication and thrombosis of inflow reconstructions in limb salvage patients. Infection was the cause of failure in 5.5% of failed grafts (1.8% of the series) and was associated with multiple reoperations. Management consisted of conservative treatment in 15 cases, with amputation resulting in seven (46%) of these. Operative treatment consisted of (A) thrombectomy with or without patch (N = 56); (B) extension with vein (N = 12); (C) replacement with vein (N = 11); or (D) extension or replacement with PTFE (N = 17). Primary patency and limb salvage of secondary procedures at 30 months after the reoperation was (A) 40%/45%; (B) 32%/43%; (C) 55%/72%; and (D) 30%/38%, respectively. Patients in Group C (replacement with vein) had an 88% 30-month patency when this was the first procedure after the failure, with limb salvage in all cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Is the preferential use of polytetrafluoroethylene grafts for femoropopliteal bypass justified?

The objective of this review is to analyze the long-term results of femoropopliteal bypass done preferentially with polytetrafluoroethylene (PTFE) grafts in patients who presumably had saphenous vein available. The results are analyzed according to preoperative variables in an attempt to determine those instances in which PTFE grafts may be preferred for the first reconstruction and to identify those patients who benefited from vein preservation. From 1979 to 1985, 146 femoropopliteal bypass operations were performed in 120 patients with 6 mm PTFE grafts used preferentially. The results with follow-up at 5 years are analyzed by actuarial methods. The patency rate at hospital discharge was 100%. The overall primary patency rate at 5 years was 57%. Reconstructions above the knee (101) and below the knee (45) had significantly different 5-year patency rates (63% vs 44%, p less than 0.03). Sixty-two reconstructions done to alleviate disabling claudication had a 5-year primary patency rate of 69% and no amputations. Eighty-one reconstructions were done to treat critical ischemia with a 5-year patency rate of 49% and a 5-year foot salvage rate of 73%. When secondary operations were required to treat graft failures, the 4-year cumulative patency rate of the secondary reconstruction was 18% when performed with a prosthetic graft, in contrast to 70% when performed with the spared saphenous vein. We conclude that femoropopliteal reconstruction with PTFE grafts is a reasonable alternative for older patients with disabling claudication. Patients with critical ischemia will likely benefit from preservation of the vein with initial femoropopliteal reconstruction done with PTFE. Staged infrainguinal revascularization for foot salvage may improve present results. In this regard the sequence PTFE-then-vein carries a higher predicted patency rate than the sequence vein-then-PTFE.

Surgical results: a justification of the surgeon selection process for the ACAS trial. The ACAS Investigators.

PURPOSE: The selection of surgeons to participate in a prospective randomized trial comparing the efficacy of a surgical method with medical management is critically important because it will have a direct impact on the outcome of the study and the future use of the operation. We report the success of the method used for selecting surgeons who participated in the Asymptomatic Carotid Atherosclerosis Study (ACAS) by examining the surgical morbidity and mortality rates and the outcome of the study. METHODS: A Surgical Management Committee established criteria for auditing surgeons who wished to participate in the study. The parameters included a minimum performance of at least 12 carotid endarterectomies (CEA) per year and an audit of each surgeon's last 50 consecutive CEAs with required documentation of a combined neurologic morbidity and mortality rate of <3.0% for asymptomatic patients and <5.0% for all indications including symptomatic patients. RESULTS: As of February 1991, 164 surgeons from 48 medical centers applied for ACAS participation. One hundred seventeen were approved, and their aggregate experience of 5641 operations yielded a combined neurologic morbidity and mortality rate of 2.3% for asymptomatic and symptomatic patients combined. The morbidity and mortality rate for CEA on asymptomatic patients was 1.7%. These surgeons, plus those recruited after February 1991, became investigators in the ACAS trial and were responsible for the surgical care of 825 patients who were randomized to the surgical arm. Seven hundred twenty-four patients actually underwent CEA. One patient (0.14%) died and ten patients (1.38%) had strokes within the 30-day perioperative interval, for a combined stroke or death incidence of 1.52%. The 5-year stroke event rate in the surgical group (including perioperative morbidity and mortality rates) was 5.1%. compared with 11% of patients treated medically, yielding a relative risk reduction of 53% in favor of surgery (p=0.004). CONCLUSIONS: A method for selecting surgeons for participation in the ACAS trial was successful in providing low perioperative morbidity and mortality rates. This materially influenced the outcome of the study in favor of CEA.